PRO-EURO DILI NET
Prospective European Drug-Induced Liver Injury Network
Financed by: European Comission
Programme: EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY (COST) 2017
Duration: October 2018 to April 2023
- RAÚL ANDRADE BELLIDO , Chair
- MARÍA ISABEL LUCENA, MC Member
- NIU HAO, Participant in work package 3
- DANIEL ENRIQUE DI ZEO SÁNCHEZ, Participant in work package 4
- AIDA ORTEGA ALONSO, Participant in work package 1,4,5
- ENRIQUE DEL CAMPO HERRERA, Participant in work package 4,5
- Inmaculada Medina-Caliz, Participant in work package 4,5
- Aurélie Papineau, Participant in work package 4,5
- Judith Adriana Sanabria Cabrera, Participant in work package 4
- Ismael Álvarez Álvarez, Participant in work package 4
- María Mercedes Robles, Participant in work package 4
- Gonzalo Matilla Cabello, Participant in work package 3
There is a clear unmet need for a deeper understanding of idiosyncratic drug-induced liver injury (DILI), a multi-layered challenge that spans the life of the drug from pre-clinical development to clinical trials and post-marketing.
The objectives of the PRO-EURO-DILI-NET Cost Action are to create a unique, co-operative, interdisciplinary European-based DILI network of stakeholders to co-ordinate efforts in DILI, to facilitate bi-directional exchange of discovered knowledge and generated hypotheses among different disciplines, and to promote clinically impactful knowledge discovery and its translation into clinical practice.
This Action will: (a) harmonize efforts for in-depth DILI phenotyping and bio-sample repository and coordinate pre-funded database/repository studies to aggregate a large number of DILI cases in a standardized manner (WG1);
(b) Establish a strategy for development, validation and performance of DILI novel biomarkers and explore multifactorial DILI risk modifiers in clinical data sets using novel approaches for future precision medicine (WG2);
(c) Facilitate clinically impactful knowledge discovery by introducing biological variations and the complexity (i.e., multi-cellular/multi-organ systems) into toxicological experiments to assess hepatotoxicity to guide future drug safety testing (WG3).
(d) Define criteria and establish endpoints to measure efficacy on novel interventions in DILI (WG4);
(e) Draft policy recommendations about near-patient testing tools.
The network will promote and coordinate a highly translational and innovative research program in Europe and beyond with the ultimate goal to pre-empt and prevent DILI, develop innovative therapeutic approaches that could improve clinical outcomes and enhance public awareness, while developing a forum for knowledge exchange and training of young European researches.